News

Press contact :
Stéphanie Moy
+33 (0)6 32 55 85 48
s.moy@quantumsurgical.com
Events

CIO 2025, October 17-19, 2025

CIO 2025 will be held in Miami, Florida, October 17 to 19.

The Symposium on Clinical Interventional Oncology (CIO) is the ultimate destination for clinicians passionate about advancing cancer through interventional oncology (IO).

Designed for practicioners at every stage of their IO journey, CIO delivers a comprehensive curriculum that spans foundational techniques to the latest innovations in robotics, systemic treatments, and emerging therapies.

Spend a weekend with experts in Miami and learn how the EPIONE® robotic platform will impact your clinical practice.

If you would like a more personalized demo, contact us at info@quantumsurgical.com and let the Quantum Surgical Team introduce you to EPIONE®, the all-in-one robotic platform designed to plan, target, deliver and confirm percutaneous ablation procedures..

We look forward to seeing you in Miami!

Event Details

Date :

  • October 17-19, 2025

Location :

  • Loews Miami Beach, Florida

Events

JFR 2025, October 3-6

The Journées Francophones de Radiologie 2025 will be held from October 3rd to 6th in Palais des Congrès de Paris (Porte Maillot, Paris, France).

Do not miss your chance to meet with all the key players in Radiology!

Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

  • Visit us at Quantum Surgical Booth at the Village de Radiologie Interventionnelle (3rd floor).
  • Discover Epione® during the Super Demo sessions hosted by some of our top users at the Agora of the Village de Radiologie Interventionnelle (information coming soon).

Event Details:

Events

WAIS 2025, September 20-24

WAIS 2025 will be held in Colorado Springs, CO, September 20-24, 2025.

The Western Angiographic & Interventional Society (WAIS) is celebrating its 55 year anniversary in 2025!

WAIS hosts an annual conference that focuses on a single general session format to connect faculty and attendees through interactive discussions and shared experiences. The 2025 Program is designed to address clinician practice gaps, as well as introduce emerging trends in image-guided therapies, patient care, and technology.

Quantum Surgical will exhibit Epione®,  the all-in-one robotic-assisted  solution which allows physicians to plan, target, deliver and confirm tumor ablation by combining the power of Navigation, Robotic-Assistance and Ablation Confirmation.

Please stop by our booth to meet with the Quantum Surgical team – we look forward to seeing you at the event!

Learn more about WAIS 2025.

Date:

  • 20-24 September 2025

Location :

  • The Broadmoor – Colorado Springs, Colorado

Events

CIRSE 2025, September 13-17

Organized by the Cardiovascular and Interventional Radiology Society of Europe, the CIRSE 2025 event is the world's biggest meeting focusing on interventional radiology and will take place in Barcelona, Spain from September 13-17, 2025.

For 40 years, the CIRSE annual congress has provided the world’s premier platform for specialists in minimally invasive image-guided procedures to meet, share and connect. Quantum Surgical is delighted to announce its renewed participation this year, underscoring our commitment to advancing medical innovation and collaboration within this dynamic community.

Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

Event Details:
  • Date: September 13-17, 2025
  • Location: Centre de Convencions International de Barcelona, Spain

Webinar

Webinar on Robotics in Image Guided Ablation

Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.

Topics include:

  • Benefits and challenges of robotics during ablation procedures
  • Learning curves
  • How to approach administration about adopting robotics
  • Case presentations
  • And live Q&A
Join us for this virtual event with live Q&A.
Limited spots. 
REGISTER NOW!
Events

ECIO 2025 - April 13-16, 2025

The European Conference on Interventional Oncology 2025 will be held in Rotterdam, The Netherlands, from April 13th to 16th, 2025.

Organized by the CIRSE, this yearly event brings together interventional radiologists, medical oncologists, surgeons, and numerous other healthcare professionals around the latest advancements in Interventional Oncology.

Don’t miss the opportunity to learn more about the Epione®, a unique robotic-assisted platform, at the ECIO:

  • ORAL PRESENTATION – Preliminary results of the EPIBONE study

Dr. Baptiste Bonnet – Gustave Roussy (Villejuif, France)
Tuesday, April 15th I 8:30 AM – 10:00 AM

  • ORAL PRESENTATION – Irreversible electroporation of liver lesions with robotic assistance: feasibility, safety and oncology outcome in a series of 22 cases

Prof. Laurent Milot – Hôpital Edouard Herriot, Hospices Civils de Lyon (Lyon, France)
Tuesday, April 15th I 5:00 PM – 6:30 PM

  • e-POSTER – Safety and Accuracy of Robotic-Assisted Microwave ablation: first American experience on 50 patients

Dr. Govindarajan Narayanan – Baptist Health (Miami, USA)

  • e-POSTER – Performance and safety of robotic-assisted CT-guided percutaneous ablation in lungs – Final results of the EGLE study

Dr. Baptiste Bonnet et al. – Gustave Roussy (Villejuif, France)

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

Détails de l'événement :

  • Date: April 13-16, 2025
  • Location: Rotterdam Ahoy Convention Centre – Rotterdam, The Netherlands
Events

SIO 2025

The SIO 2025 Annual Scientific Meeting will be held in Las Vegas, NV, from January 30th to February 3rd, 2025.

We are excited to announce our active participation in the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting.

As a dedicated non-profit association, the Society of Interventional Oncology continues to champion the advancement of interventional oncology (IO), positioning it as the fourth pillar of cancer therapy worldwide. The SIO 2025 Annual Scientific Meeting stands as the pinnacle of gatherings in interventional oncology, showcasing the latest research, fostering longitudinal learning, hosting insightful tumor boards, and providing invaluable networking opportunities with colleagues and industry professionals.

Over the span of five enriching days, dive into a realm of new skills, forge meaningful relationships, and elevate patient-care practices. Join us at our booth for a firsthand experience of our groundbreaking solutions. Learn more about Epione®, our unique robotic-assisted platform that empowers physicians to Plan, Target, Deliver, and Confirm tumor ablation.

  • Don’t miss the chance to register for the SIO hands-on workshops, designed to deepen your expertise:
    “Robotics, Navigation, Guidance, and Confirmation Hands-on”: “Image Guidance & Robotics”
    Sunday February 2nd,  January 26th, 2:30pm – 3:45pm

Visit us at our booth throughout the event, from January 31st to February 2nd, for a captivating hands-on demonstration. Experience firsthand how Epione® is revolutionizing the field of interventional oncology.

Nous nous réjouissons de vous voir à cet événement.

To register for SIO 2025, please visit: Annual Scientific Meeting

Date :

  • January 30th – February 2nd, 2025

Localisation :

  • Paris Las Vegas, Las Vegas, Nevada
Press releases

The Léon Bérard Center in Lyon, France, adopts Epione®

Montpellier, April 24, 2025 – The Léon Bérard Center (CLB), a cancer treatment center in Lyon, has just installed Epione®, the platform developed by Quantum Surgical that enables early and curative treatment of tumors. The first patients have already been treated. CLB becomes the sixth site in France to offer this minimally invasive treatment, which destroys abdominal and lung tumors by inserting a needle through the skin.

Specializing in robotics and artificial intelligence, Quantum Surgical develops the Epione robotic platform, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment is an alternative to surgery, involving the insertion of one or more needles through the skin to reach and destroy the tumor.

Epione has already been used to treat 875 patients worldwide and is now available at Léon Bérard Center in Lyon.

“The adoption of the Epione robot marks a major advancement for our department and our patients. Thanks to this cutting-edge technology, we can perform minimally invasive procedures with unmatched precision, thereby reducing risks and significantly improving patient care. This innovation strengthens our commitment to providing the highest quality of care in interventional radiology,” explains Dr. Amine Bouhamama, interventional radiologist at the Léon Bérard Center.

“At the Léon Bérard Center, we are deeply committed to offering our patients ever more advanced and compassionate care. We are therefore proud to integrate the innovation represented by Epione into our therapeutic options, providing our patients with procedures that are more precise, less invasive, and safer,” says Professor Jean-Yves Blay, General Director of the Léon Bérard Center.

“We are delighted with this new installation at the Léon Bérard Center. The deployment of a second Epione just weeks after the one at Toulouse University Hospital is a true validation of the benefits our platform offers. The entire Quantum Surgical team is thrilled that more patients can now benefit from our technology to treat their tumors,” says Bertin Nahum, President and Co-founder of Quantum Surgical.

Epione is CE-marked in Europe for abdominal and lung tumors and FDA-approved in the United States for abdominal tumors. Epione is available in about 20 hospitals worldwide including at Baptist Health South Florida in Miami, Florida and Rush University System Health in Chicago, Illinois.

About Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 130 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

More information: www.quantumsurgical.com

About the Léon Bérard Center (CLB)

The Léon Bérard Center is a member of the Unicancer network, which brings together 18 French Cancer Centers and one affiliated institution. It is recognized as a regional, national, and international center of excellence in oncology. Located in Lyon, one of France’s major cities, the CLB fulfills a threefold mission of care, research, and education, with a constant focus on improving the quality and accessibility of cancer care.

All diagnostic tests, treatments, and patient follow-up during and after illness are provided on a single site. The Center receives more than 45,000 patients each year for hospital stays, consultations, or examinations, and diagnoses over 6,000 new tumors annually.

The CLB has over 2,200 staff members, including 280 physicians, 600 researchers, and 800 caregivers. One of the Center’s strengths is its seamless integration of care and research. On-site, doctors and researchers work closely together to shorten the time between laboratory discoveries and their application to patient care. As a result, more than 2,000 patients are enrolled each year in one of the 300 open clinical trials.

Press contact Léon Bérard Center

Julie Colomb

julie.colomb@lyon.unicancer.fr

Tél.: +33 (0)4 69 85 61 85

Press releases

King’s College Hospital Becomes First in United Kingdom to Adopt Epione

London and Montpellier, June 10th, 2025 – King’s College Hospital NHS Foundation Trust has installed Quantum Surgical’s Epione® robotic platform. King’s College Hospital NHS Foundation Trust has become the first center in the UK to adopt this innovative technology to treat early-stage cancerous tumors.

Quantum Surgical, a company specializing in robotics and AI, develops the Epione® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

King’s College Hospital NHS Foundation Trust patients have benefited from these percutaneous ablation techniques for over 20 years. Thanks to Epione, King’s College Hospital can now offer patients with liver cancer this robotic-assisted technology that enhances the safety and accuracy of these procedures. Seven patients have already been treated by Dr. Praveen Peddu and his team.

Dr. Praveen Peddu, Consultant Interventional Radiologist at King’s College Hospital, explains: “Compared with conventional percutaneous ablations, this type of robotic ablation is less invasive and more precise. Patients treated with this new technology can benefit from less post-operative pain, shorter stays in hospital and better outcomes, recovering at home  in a few days. We are delighted to be able to expand the types of percutaneous minimally invasive ablative treatments for cancer we can offer to our patients at King’s, helping us improve cancer treatment and care.”

Robotic-assisted mini-invasive treatments can help the patient’s recovery with shorter hospital stay (outpatient procedure possible and reduced pain and side effects.

“We are very proud of the first installation of our Epione robotic system in the United Kingdom. We are delighted to work with King’s College Hospital NHS Foundation Trust, Dr. Peddu and his colleagues are paving the way for physicians in the UK who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives” declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione is currently used to treat tumors in the liver in about twenty cancer centers worldwide. Over 900 patients have already been treated worldwide.

Press releases

Quantum Surgical partners with the Taiwanese distributor Unison Healthcare Group to expand activities and fight cancer in Taiwan

Montpellier and Taiwan, March 20th 2025 – A specialist in the minimally invasive treatment of cancerous tumors, Quantum Surgical extends its presence in Taiwan in partnership with Unison Healthcare Group. Quantum Surgical’s robotic platform Epione is already used in fifteen cancer centers in Europe and in the USA.

Quantum Surgical develops the Epione® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

Epione can treat tumors located in the abdomen (liver, kidney, pancreas) in the lungs, and is currently used to treat tumors in the liver in about fifteen cancer centers worldwide. Over 800 patients have already been treated worldwide.

Quantum Surgical now partners with UHG to strategically expand activities in Taiwan, according to the latest statistics, the number of newly diagnosed cancer cases in Taiwan in 2022 is estimated to be 132,293, an increase of 8,531 cases compared to 2021.

Bertin Nahum, CEO and co-founder of Quantum Surgical explains “We are thrilled to expand our activities in Taiwan with Unison Healthcare Group, as our mission is to improve early-stage cancer treatment worldwide and ensure that as many cancer patients as possible can benefit from our minimally invasive technology”.

Daniel Shih, Chairman and President of Unison Healthcare Group (UHG) declares ”The partnership between UHG and Quantum Surgical’s founders began with their former venture Medtech and the ROSA surgical robot. The Group is honored to work with Quantum Surgical again to promote the minimally invasive surgical robotic system for cancer treatment. We hope that the new generation of minimally invasive cancer surgical robots will elevate the quality of Taiwan’s cancer treatment industry”.

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 10 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

Plus d'informations : www.quantumsurgical.com

About Unison Healthcare Group

Founded in 1995, Unison Healthcare Group (UHG) has always been committed to providing the highest quality healthcare services in Taiwan by upholding the brand mission of “Inspiring Healthcare for Happiness”. Since the introduction of radiological equipment in the 1960s, the Group has continued to expand from “precision diagnosis” to “precision medicine”. In 2009, UHG embarked on the era of medical robots, and has been distributing a number of high-end surgical robots for neurosurgery, orthopedics, and other medical fields, which has revolutionized the delivery of healthcare and clinical services. Meanwhile, the Group has also developed a “one-stop comprehensive service” to provide medical institutions, private organizations and individuals with a genuine “Total/Integrated Solution” for medical and healthcare services. Moreover, UHG is fully committed to promoting ESG and obtained the B Corp Certification in 2022.

Press contact Unison Healthcare Group

Athena Liu

athenaliu@unison.com.tw

Tel: +886-939392092

Press releases

Quantum Surgical Welcomes New Scientific Advisory Board Member to Expand Cancer Care

Montpellier, February 27th 2025 – Quantum Surgical, manufacturer of the Epione® platform for robotic-assisted percutaneous ablations, is proud to announce the expansion of its Scientific Advisory Board (SAB) with the appointment of  Sean Tutton, MD, FSIR, FCIRSE, a board-certified diagnostic and interventional radiologist who specializes in the treatment of cancer and non-cancer related pathologic skeletal fractures at UC San Diego Health. This appointment is a key milestone for Quantum Surgical and the company’s commitment to advancing innovation in robotic-assisted procedures for interventional radiologists and expanding access to patient care.

Interventional oncology has become highly specialized and is rapidly becoming a standard of care for many multidisciplinary cancer programs. Considered the fourth pillar of oncology, the growth of this subspecialty is similar to the evolution of surgical oncology.

“Robotics has long been established in surgical fields such as general surgery, urology, and orthopedics, so its integration into interventional radiology is a natural progression,” said Dr. Sean Tutton.

“Robotic-guided procedures in interventional oncology offer significant value to physicians, but it’s the patients who really gravitate to robotics because there is the perception of the precision, efficacy, and safety,” adds Dr. Tutton.

The Epione platform is an advanced robotic-assisted technology designed for interventional radiologists performing percutaneous ablations of abdominal tumors—a minimally invasive treatment often used with curative intent. It enhances physician support by providing real-time patient monitoring, assisting in planning an optimal trajectory, improving tumor targeting precision, increasing the accuracy of therapy delivery, and offering immediate confirmation of procedural success.

“As we continue to focus on our clinical strategy of robotic-assisted procedures, we are honored with the appointment of Dr. Sean Tutton to expand our SAB of world-renowned experts in interventional oncology. His expertise and insight will support our vision of driving the demand for minimally invasive cancer care in the US market,” says Bertin Nahum, CEO and co-founder of Quantum Surgical.

“We are honored to welcome Dr. Sean Tutton to our SAB,” said Laetitia Messner, Chief Clinical Officer at Quantum Surgical. “His expertise and insights will be invaluable in shaping Quantum Surgical’s clinical strategy and driving the adoption of Epione.”

Quantum Surgical’s Scientific Advisory Board brings together a distinguished, multidisciplinary team of global experts dedicated to advancing robotic-assisted interventional oncology. The board includes:

  • Govindarajan Narayanan, MD (USA), Chief of Interventional Oncology at Miami Cardiac and Vascular Institute Miami Cancer Institute, a part of Baptist Health South Florida
  • Steven D. Colquhoun, MD (USA), Professor of Surgical Oncology, Wellstar MCG Health Medical Center (Augusta, GA)
  • Thierry De Baère, MD (France), Professor and Interventional Radiologist at Gustave Roussy Cancer Center (Villejuif)
  • Laurent Milot, MD (France), Professor and Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon
  • Luigi Solbiati, MD, (Italy), Professor of Radiology at Humanitas University (Rozzano – Milan) (Honorary Member)

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 120 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined the governmental French Tech 2030 program in 2023, which supports top emerging actors in disruptive innovation.

The Epione platform is designed to standardize cancer care by enabling earlier and more precise interventional oncology procedures. It is FDA-cleared for CT-guided percutaneous ablation procedures in the abdomen, CE-marked for ablations in the abdomen and lung, and compatible with most ablation devices.

Plus d'informations : www.quantumsurgical.com

Corporate

An exciting and busy year 2024 at Quantum Surgical

It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:

We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!

Press releases

Cancer: The Toulouse University Hospital (France) acquires Epione®, the lung and abdominal tumor-treating robot

Montpellier, February 4, 2025 – As part of its STARThu program, the Toulouse University Hospital (CHU) has just acquired Epione®, the robot from Quantum Surgical designed to assist physicians in the curative and early treatment of abdominal and lung tumors. The CHU is the first center in Occitanie to offer patients this minimally invasive, safe, and effective surgery.

To destroy an abdominal or lung tumor, a percutaneous tumor ablation (through the skin) can be performed. This is a minimally invasive radiological procedure aimed at destroying the cancerous tumor using a needle, either through heat or cold. Therefore, it is essential to guide this needle precisely to the location of the tumor. This process is often long and challenging, as tumors can be small and “poorly located.”

This is where the robotic platform Epione® comes into play. Using imaging technology, the Epione® robot assists physicians by:

  • Visualizing the area to be treated with a 2D/3D image fusion software and ensuring the precise positioning of the ablation needle.
  • Confirming the success of the treatment.

For patients, this means access to a safe, effective, and minimally invasive treatment.

As part of its STARThu plan, the Toulouse University Hospital (CHU) has acquired Epione® to further develop robot-assisted procedures within its facilities, aiming to offer ever more advanced treatments to its patients. With this acquisition, the CHU becomes the fifth center in France to offer this innovative treatment.

Jean-François Lefebvre, General Manager of Toulouse University Hospital (CHU) : By integrating robotic solutions like Epione® in interventional imaging, the Toulouse University Hospital reaffirms its commitment to medical and technological innovation. This major advancement reflects our ongoing dedication to offering our patients less invasive, yet increasingly precise and effective treatments, particularly in oncology. I would like to commend Professor Mokrane and his teams for implementing this cutting-edge technology. As part of its 2023-2028 institutional project and through the STARThu plan (Strategic Plan for Robotic and Technological Interventional Assistance in University Hospitals), the CHU of Toulouse confirms its status as a leading reference center, ensuring both modernity and medical excellence.”

Professor Fatima Mokrane, radiologist at Toulouse University Hospital (CHU), explains: “Epione® is a unique therapeutic solution that allows us to treat early-stage and hard-to-reach tumors in a minimally invasive and highly precise manner. Thanks to this technology, we will be able to treat more patients in Toulouse, and in a more comfortable way.”

Bertin Nahum, President and Co-founder of Quantum Surgical, states: “We are delighted with this new acquisition by the Toulouse University Hospital, the first in Occitanie. The entire Quantum Surgical team is thrilled that our technology is now accessible to more patients for the treatment of their tumors.”

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 120 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical a reçu le prestigieux Prix Galien USA en 2022, l'équivalent du Prix Nobel pour la recherche biopharmaceutique, et a rejoint en 2023 le programme gouvernemental French Tech 2030 qui soutient les meilleurs acteurs émergents en matière d'innovation de rupture.

Plus d'informations : www.quantumsurgical.com

About the Toulouse University Hospital (CHU de Toulouse)

The Toulouse University Hospital (CHU) is a leading healthcare and academic institution, deeply rooted in the city of Toulouse and the Occitanie region. It fulfills its public service missions by providing medical care and prevention, training future healthcare professionals, and actively contributing to innovation and medical research.

In the field of oncology, the CHU dedicates up to 25% of its overall activity to cancer treatment. Its healthcare services are organized across three hospital sites labeled as “Institut Universitaire du Cancer – Toulouse”:

  • IUCT-Rangueil-Larrey
  • IUCT-Purpan
  • IUCT-Oncopole

These sites operate in a complementary manner, avoiding duplication and promoting a multidisciplinary and coordinated approach to cancer treatment.

In western Occitanie, the CHU de Toulouse handles 39% of all cancer-related hospitalizations, making it the leading center for oncology care in the region. With 1,244 patients enrolled in clinical trials and 456 active research projects, the CHU is strongly committed to advancing knowledge and treatments to better meet patients’ needs.

Ranked the best hospital in France (Le Point 2024 ranking), the CHU de Toulouse is also one of the largest employers in the Occitanie region, with a workforce of 16,000 professionals, including 4,000 physicians and 12,000 hospital staff, whose expertise and dedication drive its excellence.

Press contact Toulouse University Hospital (CHU)

Joséphine Enard
Enard.j@chu-toulouse.fr
Tel. : +33 (0)5 61 77 80 27

Press releases

Rush University System for Health Becomes First in Midwest to Acquire Quantum Surgical's Robotic Platform for Cancer Tumors in the Abdomen

Chicago and Miami, November 12, 2024 – Rush University System for Health, a nationally recognized leader in providing high-quality care, announced today that it has acquired QuantumSurgical’s Epione®p latform. Rush University Medical Center is among a select group of hospitals nationwide — and the first in the Midwest — to adopt this innovative technology.

The Epione platform is a state-of-the-art robotic-assisted technology for interventional radiologists who perform percutaneous ablations of abdominal tumors, a minimally invasive treatment often used with curative intent. Epione supports physicians in planning the optimal targeting of a tumor and monitoring the patient’s position in real-time. The robotic arm uses this information to precisely position the physician’s instrumentation. This enables increased accuracy of the ablation procedure and allows for immediate confirmation if the tumor ablation was successful.

“Rush’s interventional radiology program is one of the best programs in the country, excelling in clinical interventional care, education with one of the largest and most sought-after residency programs, and robust research activities with multiple ongoing clinical trials,” says Bulent Arslan, MD,FSIR, director of vascular and interventional radiology at Rush. “We are very happy to be first in the region to provide this new technology to our patients that will make their experience better, more efficient, and safer. Robotic systems have been in surgical care for many years and now are available for the interventional care of patients. We treat complex lesions throughout the body with ablative therapies, but it is not always easy to reach our targets, and there is some risk involved in the process. Using Epione, we will be able to reach most locations with computerized guidance using patients’ existing CT or MRI images relatively easily and with less risk. This is an evolution in cancer patient care, and we are excited to be the first in the Chicago area to offer it.”

While surgery may be an option for some, it often involves higher costs and longer hospital stays. Epione is a minimally invasive option for patients with small tumors. Patients can often go home the same day with nothing more than a Band-Aid.

"We are thrilled to celebrate this milestone as Quantum Surgical’s Epione platform arrives in the Midwest," said Bertin Nahum, CEO and Co-founder of Quantum Surgical. "We are excited to collaborate with the esteemed team at Rush University System for Health, as our mission is to ensure that as many cancer patients as possible can benefit from this minimally invasive technology."

 

About Quantum Surgical

Quantum Surgical was founded in 2017 by CEO and co-founder Bertin Nahumand a team of pioneering innovators specializing in developing and commercializing advanced medical robotics. Headquartered in Montpellier, France, and Miami, Florida, Quantum Surgical has a growing team of over 120 dedicated professionals.

The Epione platform is designed to revolutionize cancer care by enabling earlier and more precise treatments. Epione is FDA-cleared for CT-guided percutaneous ablation procedures in the abdomen and is compatible with most FDA-approved ablation devices.

More information: www.quantumsurgical.com

Press Contact Quantum Surgical

Stéphanie Moy          

s.moy@quantumsurgical.com

Tel.: +33 (0)6 32 55 85 48

About Rush

Rush University System for Health brings together the brightest minds in medicine, research and academics. Driven by discovery, innovation and a deep responsibility for the health of our communities, RUSH is a national leader in outstanding patient care, education, research and community partnerships and in empowering a new generation of health care providers.

RUSH is a nonprofit health system that includes Rush University Medical Center, Rush University, Rush Copley Medical Center and Rush Oak Park Hospital, as well as an extensive provider network and numerous outpatient care facilities. Rush University Medical Center is ranked among the top hospitals in the nation by U.S. News & World Report and consistently is named among the top academic medical centers for excellence in patient care by Vizient Inc. anda Top Teaching Hospital by The Leapfrog Group. Rush University comprises three colleges: Rush Medical College, the College of Nursing and the College ofHealth Sciences. 

 

Press releases

Quantum Surgical launches a clinical study for the use of its Epione® robot in the treatment of bone tumors

Montpellier, September 19, 2024 – Quantum Surgical is launching a new clinical study for the treatment of bone tumors and metastases, assisted by the Epione® platform. Conducted in parallel at the Paoli-Calmettes Institute (Marseille) and the Hospices Civils de Lyon, the study is coordinated by Dr. Baptiste Bonnet, an interventional radiologist at Gustave Roussy (Villejuif), ranked fourth best cancer hospital in the world in 2023[1].This study will evaluate the clinical performance and safety of the Epione platform for treating these lesions.

Although primary bone cancer is relatively rare, the development of bone metastases—often occurring several months or years after the initial cancer—is common, affecting one-third of cancer patients[2].

Specializing in medical robotics and artificial intelligence, Quantum Surgical develops the Epione technology, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment involves inserting one or more needles through the skin and into the tumor to destroy it.

Epione is CE marked for ablation indications in the abdomen and lung, and FDA-cleared for ablation indications in the abdomen. More than 575 patients have benefited from this curative treatment worldwide.

This new clinical study “Epibone” will assess the performance of the Epione platform to treat bone tumors and metastases, with the ultimate goal of obtaining an extension of its market approvals in Europe and the United States.

“This study is a new step in the development of Quantum Surgical, and I am pleased that it is being conducted with three of our valued partners, whose teams are well acquainted with our technology and its potential to treat more patients,” explains Bertin Nahum, CEO and Co-founder of Quantum Surgical.

“The Epibone study represents a significant advance in the evolution of robot-assisted guidance, focusing on a topic that is close to our hearts: percutaneous bone procedures. It is likely one of the most ambitious and relevant indications forthe Epione robotic platform!” elaborates Dr. Baptiste Bonnet, Interventional Radiologist at Gustave Roussy.

Laetitia Messner, Clinical Director at Quantum Surgical, adds: “We are really eager to validate the effectiveness of Epione in treating bone lesions. Given that one-third of cancer patients suffer from bone metastases, many patients could benefit from our innovative technology.”

Epione is currently used at the Gustave Roussy Cancer Center in Villejuif, the Hospices Civils de Lyon, the Paoli-Calmettes Institute in Marseille, and the CHU Amiens-Picardie.

Epione is also used in Miami and recently available in two renowned cancer centers in the USA.

 

About Quantum Surgical                                                                              

Quantum Surgical is a French company specializing in medical robotics and AI,co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione platform is dedicated to the curative and early treatment of cancers.

Quantum Surgical offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better-targeted, and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined the governmental French Tech 2030 program in 2023, which supports top emerging actors in disruptive innovation.

More information: www.quantumsurgical.com

[1] GustaveRoussy, 2023

[2] InfoCancer

Press releases

New Study: American Public Largely Supportive of the Use of Surgical Robots in Cancer Treatment

Montpellier, August 7th 2024 – To better understand public apprehension towards cancer and their knowledge of treatments, the medical robotics company Quantum Surgical surveyed them. Conducted on both sides of the Atlantic, the YouGov study reveals that a majority of American and French citizens fear that future generations will suffer from cancer, unlike Germans. Additionally, over half of the American believe that robotic solutions can enhance cancer treatments. However, data also shows that percutaneous ablation, a minimally invasive technique significantly reducing recovery time, is still relatively unknown in the U.S.

 

Cancer: A Major Concern for a Majority of American People

While the WHO predicts a 77%increase in cancer cases worldwide by 2050 [1], 53% of Americans fear being diagnosed with cancer, a concern shared by the French (54%). Furthermore, over half of American people express concern for the young people close to them; the concern reaches nearly two-thirds in France. This contrasts significantly with Germany, where only 37% fear for their younger generations.

Even more surprising: 47% of Americans aged 18 to 24 express concerns about future generations, compared to 74% of young French.

 

Americains and French More Confident Than Germans in Robotics to EnhanceCancer Treatments

A majority of Americans and French perceive robotics as an effective solution to improve cancer treatments (56% and 53%r espectively). This enthusiasm is particularly notable among American men (59% compared to 52% among women). Similar gender disparities exist in France where it reaches the significant disparity of 63% versus 44%.

In contrast, only 44% of German respondents believe that robotics is an effective solution to improve cancer treatments.

 “The WHO’s predictions suggest that cancer will unfortunately be a reality for many people. The fact that the majority of Americans believe that robotics and AI can make cancer treatments more effective is very encouraging. At Quantum Surgical, we have demonstrated with Epione® how technology can concretely assist physicians in improving cancer treatmentfor patients,” said Bertin Nahum, President and Co-founder of QuantumSurgical.

Percutaneous Ablation: A Future Solution Little Known in the United States Compared to OtherCountries

Only7% of American respondents are familiar with percutaneous ablation as a cancer treatment method, a figure that rises to 11% among cancer patients. This percentage is significantly lower than the 23% of French who report knowing about this new form of therapy and is similar to Germans (6%).

In fact, percutaneous ablation is the least known cancer treatment among the Americans, in comparison to other therapies: 77% are familiar with chemotherapy, 68% with surgery, 59% with bone marrow transplant, 53%with radiotherapy, 35% with immunotherapy and 30% hormone therapy.

This technique, currently under recognized and underutilized globally, offers numerous benefits. Bertin Nahum, CEO and co-fondateur de Quantum Surgical, explains, “The challenge now is to democratize assisted percutaneous ablation, a minimally invasive technique that destroys cancerous tumors by inserting one or more needles through the skin. The patient benefits of these minimally invasive treatments are manifold: fewer complications and pain post-procedure, reduced scarring, shorter hospital stays, and faster recovery.

Epione® is CE marked in Europe for abdominal and lung tumors, and FDA authorized for abdominal tumors. Epione® is available at the Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida, and three hospitals in France.

Alcohol Consumers Less Anxious… in France!

What about the respondent profiles? In the U.S., 57% and 58% of smokers and heavy alcohol consumers fear being diagnosed with cancer. This statistic drops at 45% in Germany for both categories. Surprisingly, in France, while 57%of smokers fear future cancer diagnosis, only 45% of heavy alcohol consumers share this concern. However, the link between alcohol consumption and cancer is clearly established. It is responsible for 7.1% of cancers in Europe [1] and approximately 6% of all cancers and 4% of all cancer deaths in the United States [2].

 

Methodology

The Quantum Surgical study was conducted online from February 20 to 21, 2024 with over 4,000 respondents in France, Germany, and the United States.

 

About Quantum Surgical                                                                              

Quantum Surgical is a French company specialized in medical robotics and AI, co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione® platform is dedicated to the curative and early treatment of cancers.

Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

For more information : www.quantumsurgical.com

Press Contact Quantum Surgical

Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33(0)6 32 55 85 48

Corporate

An exciting and busy year 2024 at Quantum Surgical

It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:

We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!

Corporate

‘I Literally Didn’t Have Any Organs Left to Take Out’: How Epione®, a Minimally Invasive Robotic-Assisted Ablation Technology Transformed a Cancer Patient’s Life

A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.

For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.

Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.

Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.

“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”

For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.

“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.

Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.

Events

CIO 2025, October 17-19, 2025

CIO 2025 will be held in Miami, Florida, October 17 to 19.

The Symposium on Clinical Interventional Oncology (CIO) is the ultimate destination for clinicians passionate about advancing cancer through interventional oncology (IO).

Designed for practicioners at every stage of their IO journey, CIO delivers a comprehensive curriculum that spans foundational techniques to the latest innovations in robotics, systemic treatments, and emerging therapies.

Spend a weekend with experts in Miami and learn how the EPIONE® robotic platform will impact your clinical practice.

If you would like a more personalized demo, contact us at info@quantumsurgical.com and let the Quantum Surgical Team introduce you to EPIONE®, the all-in-one robotic platform designed to plan, target, deliver and confirm percutaneous ablation procedures..

We look forward to seeing you in Miami!

Event Details

Date :

  • October 17-19, 2025

Location :

  • Loews Miami Beach, Florida

Events

JFR 2025, October 3-6

The Journées Francophones de Radiologie 2025 will be held from October 3rd to 6th in Palais des Congrès de Paris (Porte Maillot, Paris, France).

Do not miss your chance to meet with all the key players in Radiology!

Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

  • Visit us at Quantum Surgical Booth at the Village de Radiologie Interventionnelle (3rd floor).
  • Discover Epione® during the Super Demo sessions hosted by some of our top users at the Agora of the Village de Radiologie Interventionnelle (information coming soon).

Event Details:

Events

WAIS 2025, September 20-24

WAIS 2025 will be held in Colorado Springs, CO, September 20-24, 2025.

The Western Angiographic & Interventional Society (WAIS) is celebrating its 55 year anniversary in 2025!

WAIS hosts an annual conference that focuses on a single general session format to connect faculty and attendees through interactive discussions and shared experiences. The 2025 Program is designed to address clinician practice gaps, as well as introduce emerging trends in image-guided therapies, patient care, and technology.

Quantum Surgical will exhibit Epione®,  the all-in-one robotic-assisted  solution which allows physicians to plan, target, deliver and confirm tumor ablation by combining the power of Navigation, Robotic-Assistance and Ablation Confirmation.

Please stop by our booth to meet with the Quantum Surgical team – we look forward to seeing you at the event!

Learn more about WAIS 2025.

Date:

  • 20-24 September 2025

Location :

  • The Broadmoor – Colorado Springs, Colorado

Events

CIRSE 2025, September 13-17

Organized by the Cardiovascular and Interventional Radiology Society of Europe, the CIRSE 2025 event is the world's biggest meeting focusing on interventional radiology and will take place in Barcelona, Spain from September 13-17, 2025.

For 40 years, the CIRSE annual congress has provided the world’s premier platform for specialists in minimally invasive image-guided procedures to meet, share and connect. Quantum Surgical is delighted to announce its renewed participation this year, underscoring our commitment to advancing medical innovation and collaboration within this dynamic community.

Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

Event Details:
  • Date: September 13-17, 2025
  • Location: Centre de Convencions International de Barcelona, Spain

Events

ECIO 2025 - April 13-16, 2025

The European Conference on Interventional Oncology 2025 will be held in Rotterdam, The Netherlands, from April 13th to 16th, 2025.

Organized by the CIRSE, this yearly event brings together interventional radiologists, medical oncologists, surgeons, and numerous other healthcare professionals around the latest advancements in Interventional Oncology.

Don’t miss the opportunity to learn more about the Epione®, a unique robotic-assisted platform, at the ECIO:

  • ORAL PRESENTATION – Preliminary results of the EPIBONE study

Dr. Baptiste Bonnet – Gustave Roussy (Villejuif, France)
Tuesday, April 15th I 8:30 AM – 10:00 AM

  • ORAL PRESENTATION – Irreversible electroporation of liver lesions with robotic assistance: feasibility, safety and oncology outcome in a series of 22 cases

Prof. Laurent Milot – Hôpital Edouard Herriot, Hospices Civils de Lyon (Lyon, France)
Tuesday, April 15th I 5:00 PM – 6:30 PM

  • e-POSTER – Safety and Accuracy of Robotic-Assisted Microwave ablation: first American experience on 50 patients

Dr. Govindarajan Narayanan – Baptist Health (Miami, USA)

  • e-POSTER – Performance and safety of robotic-assisted CT-guided percutaneous ablation in lungs – Final results of the EGLE study

Dr. Baptiste Bonnet et al. – Gustave Roussy (Villejuif, France)

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

Détails de l'événement :

  • Date: April 13-16, 2025
  • Location: Rotterdam Ahoy Convention Centre – Rotterdam, The Netherlands
Events

SIO 2025

The SIO 2025 Annual Scientific Meeting will be held in Las Vegas, NV, from January 30th to February 3rd, 2025.

We are excited to announce our active participation in the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting.

As a dedicated non-profit association, the Society of Interventional Oncology continues to champion the advancement of interventional oncology (IO), positioning it as the fourth pillar of cancer therapy worldwide. The SIO 2025 Annual Scientific Meeting stands as the pinnacle of gatherings in interventional oncology, showcasing the latest research, fostering longitudinal learning, hosting insightful tumor boards, and providing invaluable networking opportunities with colleagues and industry professionals.

Over the span of five enriching days, dive into a realm of new skills, forge meaningful relationships, and elevate patient-care practices. Join us at our booth for a firsthand experience of our groundbreaking solutions. Learn more about Epione®, our unique robotic-assisted platform that empowers physicians to Plan, Target, Deliver, and Confirm tumor ablation.

  • Don’t miss the chance to register for the SIO hands-on workshops, designed to deepen your expertise:
    “Robotics, Navigation, Guidance, and Confirmation Hands-on”: “Image Guidance & Robotics”
    Sunday February 2nd,  January 26th, 2:30pm – 3:45pm

Visit us at our booth throughout the event, from January 31st to February 2nd, for a captivating hands-on demonstration. Experience firsthand how Epione® is revolutionizing the field of interventional oncology.

Nous nous réjouissons de vous voir à cet événement.

To register for SIO 2025, please visit: Annual Scientific Meeting

Date :

  • January 30th – February 2nd, 2025

Localisation :

  • Paris Las Vegas, Las Vegas, Nevada
Press releases

Quantum Surgical obtains CE mark approval to treat patients with lung tumors using its Epione® robot

Montpellier, September 7th 2023 – French medical robotics company Quantum Surgical has obtained CE mark approval for the expanded use of its robotic platform, Epione®, in the treatment of lung tumors. With over 2 million new cases worldwide in 2020, including approximately500,000 in Europe, lung cancer is the leading cause of cance- related mortality[1]. This new feature will be presented with related clinical study results at the CIRSE 2023 conference in Copenhagen from September 9th to 13th by Dr. Bonnet, interventional radiologist at Gustave Roussy.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allow sphysicians to treat inoperable tumors that are particularly difficult to reach,due to their size or their location, at an early stage, in a simple and effective way.  

Epione® can be used to treat abdominal tumors (including theliver, kidneys, and pancreas) and over 200 patients have already been treated inFrance and the United States.

The CE mark approval for lung tumors will expand thisinnovative, targeted, and minimally invasive treatment to new patients inEurope.

It is based on a clinical study conducted at Gustave Roussy, the leading cancer center in Europe (third worldwide), the results of which will be presented during the international scientific conference organized by CIRSE(Cardiovascular and Interventional Radiological Society of Europe).

"With Epione®, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe" said Bertin Nahum, President and Co-founder of Quantum Surgical.

“Patients were treated at Gustave Roussy with thermal destruction of lung metastases as part of a clinical study investigating the feasibility and safety of robotic guidance. In this ongoing study, the Epione® robot has consistently enabled technical success and has proven to be safe. The Epione® robot could enhance the minimally nvasive management of small and hard-to-reach lung tumors," stated Professor Thierry De Baère, Interventional Radiologist in the Department of Therapeutic Imaging at Gustave Roussy and member of the scientific advisory board of Quantum Surgical.

Laetitia Messner, Chief Clinical Officer of Quantum Surgical, explains, "Coordinated by Professor De Baère, the clinical study has demonstrated the clinical performance and safety of Epione® in the treatment of lung tumors. The CE mark approval proves the relevance and effectiveness of Epione®, which will enable us to offer innovative, targeted, and less invasive treatments to new patients."

Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or theirl ocation.

Relying on the know-how of the practitioner,Epione® integrates all the steps of a percutaneous ablation procedure in asingle platform: planning, targeting, ablation, confirmation.

[1] Globocan 2020

Press releases

Cancer: 50 patients treated with the Epione® robot from Quantum Surgical at the Hospices Civils de Lyon

Montpellier, June 13, 2023 – A 50th patient has been treated using the Epione® robot from Quantum Surgical by the team of Pr. Laurent Milot, Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon (France), highlighting a successful collaboration only 8 months post-acquisition.

Installed in November 2022, the team of the Hospices Civils de Lyon (HCL, France) are convinced of the value of this innovative platform from Quantum Surgical and celebrating that 50 patients have benefited from Epione®.Epione® can be used to treat early-stage abdominal tumors that are inoperable or particularly difficult to reach, due to their size or location.

HCL is the second hospital in the world offering this revolutionary platform to their patients. The first Epione® robot was acquired by the Institut Gustave Roussy (France) in January 2022 where the team has already treated more than 100 patients. The very first patient in the United States was also successfully treated using the Epione® robot at Baptist Hospital in Miami (Florida) last month.

Beyond the new procedural advantages it provides, Epione® makes it possible to offer patients a minimally invasive treatment. It improves their comfort and facilitates their recovery, due to the absence of surgery.

For physicians and hospitals, Epione® combines advanced robotic assistance with image-guided navigation and ablation confirmation tools to promote the standardization of minimally invasive tumor ablation procedures. This is a major challenge given that more than 4 million abdominal cancers are diagnosed each year in the world[1].

“I am very pleased with this milestone, which above all underlines the perfect match between the HCL teams and the Epione® robot, which delivers all its promises. We are very excited to continue to explore the many benefits of Epione® and to support the next steps in the development of robotics in interventional radiology. This will undoubtedly lead to significant progress and extend hope for patients we do not have treatment solutions for so far” explains Prof. Laurent Milot, Deputy Chief Vascular & Interventional Radiology.

“The implementation of the Epione® robot within the Hospices Civils de Lyon is a success: in eight months, 50 patients have already benefited from our technology, as part of their cancer treatment. Pr. LaurentMilot's teams are particularly enthusiastic. We are delighted with this collaboration, which improves access to care and patient comfort” said Bertin Nahum, president and co-founder of Quantum Surgical.

[1] Source: GlobalCancer Observatory

Press releases

First patient treated in the United States with Quantum Surgical’s Epione® robot

Montpellier, May 24, 2023 – Dr. Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute, successfully treated the first patient in the US with a liver tumor using Quantum Surgical’s Epione® robot. The procedure took place at Baptist Health South Florida in Miami, Florida, a few days after the Food and Drug Administration cleared Epione® robot for treatment of all abdominal cancers.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.  

More than 150 patients have already been treated with the Epione® robot in Europe, and Dr. Narayanan successfully treated the first patient in the US.

I am honored to be the first physician to utilize Epione® in the United States as this robotic-assisted equipment is going to change the way we deliver effective treatments to our patients for cancerous tumors,” said Dr. Narayanan. “Baptist Health has always been at the forefront when it comes to providing the very best care to the South Florida community and beyond. I am proud to be a part of such an incredible team.”

"We are very proud of this first intervention with our Epione® robot in the US! We are delighted to have been able to work with Dr. Narayanan and Baptist Health South Florida, renowned experts. This first intervention coincides with the FDA extension clearance to deploy our robotic solution in the United States. Dr. Narayanan is paving the way for physicians who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives" declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione® is a robot-assisted technology designed to plan, target, perform and confirm tumor ablation. Epione® enables physicians to perform percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin into the tumor to destroy it.

Epione® is currently available in Europe and the United States for treatment of all abdominal cancers. More than 4 million abdominal cancers occur each year worldwide[1].

[1] Source: Global Cancer Observatory

 

Press releases

FDA clears Quantum Surgical’s Epione® robot for all abdominal cancers

Montpellier, May 3rd, 2023 - Quantum Surgical, a French medical robotics company, has received an extension of authorization from the US Food and Drug Administration (FDA) for its Epione® robot, which can now treat abdominal cancers. Millions of patients could benefit from Epione® treatment worldwide

.

Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.

Available in Europe and the United States, the Epione® robot has already been used to treat more than 150 patients with liver or kidney cancer.

The extension of the Food and Drug Administration (FDA) authorization allows the commercial sale and use of theEpione® robot in the United States to treat cancers of the entire abdomen. The abdomen is the space between the thorax and the pelvis, and includes in particular the following organs: liver, kidneys and adrenal glands, pancreas.

"We are very pleased to receive the FDA clearance. This decision allows physicians to now treat all abdominal tumors at an early stage and will accelerate the implementation of our innovative Epione® robotics solution in the United States. And ultimately, enable more patients to benefit from innovative and less invasive treatments" says Bertin Nahum, president and co-founder ofQuantum Surgical.

This authorization is supported by clinical data from the Gustave Roussy Cancer Center.

[1] Source: Global Cancer Observatory

Press releases

Quantum Surgical announces the ongoing clinical trial at Gustave Roussy to extend the use of its medical robot Epione® in treating lung metastases

Montpellier, France, April 18th, 2023 - Quantum Surgical announces the ongoing clinical trial for the treatment of lung metastases assisted by the Epione® robot. The study is coordinated by Professor Thierry de Baère, Head of the Therapeutic Imaging Department at Gustave Roussy (Villejuif, France), ranked world's third best cancer hospital in 20231. This study will evaluate the clinical performance and safety of the Epione® device for the treatment of these tumors.

Epione® is a robotic platform capable of assisting interventional radiologists in planning and performing minimally invasive procedures for the percutaneous ablation of tumors in the abdomen. Available in France and the United States, the Epione® robot has already been used in procedures on more than 150 patients with liver or kidney cancer. With this study, Quantum Surgical aims to obtain an extension of its marketing authorizations in Europe and the United States with an indication extended to the treatment of lung tumors.

With more than 2 million new cases worldwide in 2020, including approximately 500,000 in Europe, lung cancer is the leading cause of death for cancer patients (18%)2.

"This study sets a new milestone in the development of Quantum Surgical, and I am proud that it is being done in collaboration with Gustave Roussy, whose teams see the full potential of our technology. This is another step towards the dissemination of our innovation to other cancer patients” says Bertin Nahum, President and co-founder of Quantum Surgical.

Gustave Roussy dans le TOP 3 mondial des hôpitaux en cancérologie | Gustave Roussy

Globocan 2020

Press releases

Robert Thompson and Joseph de Vivo have joined Quantum Surgical’s Board of Directors

Montpellier, April 13th 2023 - Quantum Surgical, the Medical Robotic company dedicated to the curative and early treatment of cancers, has appointed Robert Thompson and Joseph de Vivo and on its Board of Directors as Independent Board Members.

Robert Thompson (Bob) is an accomplished marketing and business development leader and brings Quantum Surgical his experience in product development and commercialization in the medtech industry. He previously served as President-Ultrasound Siemens Healthineers, senior leadership positions at GE Healthcare and medical device start-ups.

“I am excited to join such a talented and visionary team. The innovative solutions developed by Quantum Surgical have the potential to  transform cancer treatments by bringing a new standard of minimally invasive care  of cancer patients worldwide” says Robert Thompson.

 Joseph de Vivo brings over 30 years of experience in medical device, robotics and digital health industries. He was most recently Executive Chairman of Caption Health, President of Hospitals and Health Systems for Teladoc Health and CEO of In Touch Health. He previously served as CEO of Angiodynamics and President of Smith & Nephew Orthopedics. Mr De Vivo currently serves as the Treasurer of the American Telemedicine Association and on the Board of Governors for St Jude Children’s Research Hospital. 

“The arrival of Robert and Joseph, two experienced healthtech leaders among our Board Members is a real opportunity for Quantum Surgical and will directly serve our strategy and our development, particularly in the United States”, said Bertin Nahum, CEO and Co-Founder of Quantum Surgical.

Press releases

Epione®, Quantum Surgical’s medical robot, settled in Hospices Civils de Lyon (HCL)

Montpellier, France November 16th, 2022 - Civil Hospitals of Lyon, France (HCL ) have aquired Epione, the robotic platform developed by Quantum Surgical (QS) that is designed to enable minimally invasive ablations of tumors in the abdomen. This partnership between HCL and QS will allow more patients to benefit from Epione, an innovative platform allowing physicians to plan, target, deliver and confirm ablation treatment in a moresecure and precise manner.  Epione is currently utilized to target liver tumors but will be expanded to the treatment of kidney, lungs and pancreas as the radiologists at CHU Lyon expand their robotic interventional oncology practice.

HCL ranks asthe second largest University hospital in France and represents the second hospital in the world to offer this groundbreaking platform.  The first Epione robot was acquired by Gustave Roussy in January 2022 and the team is approaching their 100throbotic procedure.

"This new acquisition of Epione is a major step for QS and a full validation of the key benefits that Epione offers.  It is a great honor to have our robotic system acquired by one of the top medical robotic institutions in France.  The most exciting part of this story is that patients will now have a powerful new technology that can offer curative treatments by robotically navigating to destroy tumors while sparing surrounding healthy tissue" says Bertin Nahum, co-founder and CEO of Quantum Surgical.

"Epione® is a unique percutanueous robotic solution […] Currently only few experts radiologists  perform these treatments. Robotics will allow to standardize these treatments and more radiologists will thus be able to perform these cases especially the more complex cases on tumors which currently would not be treated . This will allow us to help and cure more patients" says Pr. Laurent Milot, deputy Head of Medical and interventional imagingDepartment-  CHU  Lyon.

Press releases

Quantum Surgical awarded prestigious Prix Galien USA 2022

Montpellier, France, October 28, 2022 - Quantum Surgical has been awarded the Prix Galien USA 2022, in the medtech start-up category, for its Epione® robotic platform, dedicated to the curative and early treatment of abdominal cancer and in particular liver cancer.

Considered to be the equivalent of the Nobel Prize in biopharmaceutical research, the Prix Galien highlights unique solutions and individuals who have influenced healthcare through innovation. Each year, the award recognises tomorrow's medical excellence in all areas of healthcare: drugs, medical devices and e-health.  

The Prix Galien USA awards were presented to the winners on the evening of Thursday October 27 in New York at a ceremony at the Museum of Natural History.

"This award is an honor, and a recognition of the immense work Quantum Surgical has accomplished since 2017 without ever deviating from our mission: to provide access to minimally invasive treatments to as many cancer patients as possible. In five years, we have developed a robotic platform that is unique in the world, forged numerous scientific and commercial partnerships, and received support from international funds including Ally Bridge Group and the EIB. We have been able to deploy a new solution for curative and early treatment of abdominal cancers in Europe, the United States and China, alongside the most eminent interventional radiologists. I would like to pay tribute to them: they play an essential role in enabling cancer patients to benefit from innovative, better targeted and less aggressive treatments," says Bertin Nahum, co-founder and CEO of Quantum Surgical.

Thanks to the scientific partnerships developed by Quantum Surgical with the Montpellier University Hospital and the Gustave Roussy Institute in Villejuif, almost 100 patients with abdominal cancer have been treated with Epione® to date. Quantum Surgical plans to extend the indications of its technology to other cancers and to add decision support functions based on artificial intelligence algorithms. This is a public health issue, as the number of liver cancers in the world is expected to increase by 55% by 2040, as a study in theJ ournal of Hepatology recently pointed out.

Press releases

Quantum Surgical inaugurates its new headquarters and celebrates five years of growth

Montpellier, France, October 4, 2022 – Quantum Surgical, a French medical robotics company and the creator of Epione®, a robotic platform for the percutaneous ablation of cancerous tumors, officially inaugurated its new headquarters on Monday, October 3, 2022 in Montpellier.

Bertin Nahum, President and Co-founder of Quantum Surgical, together with his partners, unveiled the new “Quantum Surgical Campus” yesterday in the presence of Michaël Delafosse, Mayor of Montpellier and President of Montpellier Méditerranée Métropole.

“Our campus is now fully aligned with our industrial growth and the pace of our business development: 2,400 m², including 670 m² exclusively dedicated to the production line of our Epione® robot, and 950 m² for housing our research and development activities. We are proud to operate in a space that brings together cutting-edge technology, industrialization, and excellence in innovative healthcare,” says Bertin Nahum, President and Founder of Quantum Surgical.

This new milestone, which also marked the celebration of Quantum Surgical’s fifth anniversary, reflects the scale-up the company has achieved in recent months. Quantum Surgical continues its expansion in France, Europe, the United States through a subsidiary, and in China through a joint venture. The company now has over 100 employees.

Thanks to the scientific partnerships developed by Quantum Surgical — notably with Montpellier University Hospital (CHU) and the Gustave Roussy Institute in Villejuif — more than 60 patients with abdominal cancers have already benefited from treatment using Epione®.

Press releases

KPMG Top Tech Tomorrow 2022

Montpellier, July 25, 2022 - Quantum Surgical is proud to be recognized as one of the #TopTechTomorrow2022 winners by KPMG, a ranking that highlights the champions of Tech in France and future European giants of tomorrow!

This award is hand selected by a panel of experts from the financial community, from a selection of more than 1000 innovative companies and based on a quantitative and qualitative multi-criteria analysis, Quantum Surgical listed among the 85 most promising French Tech companies of this 4th edition of the barometer published by KPMG!

The list of winners is available here : Top Tech Tomorrow 2022 – KPMG France (home.kpmg)

Press releases

Quantum Surgical receives FDA 510(k) clearance for the Epione® robot designed for cancer treatment

Montpellier, France, March 22, 2022 – Quantum Surgical, an innovative medical robotics company, announced today the US Food and Drug Administration (FDA) 510(k) clearance for Epione®, a new category of interventional oncology robotics dedicated to minimally invasive liver cancer treatment.

"This clearance enables interventional oncologists to access state-of-the-art technology that has the potential to improve clinical outcomes and patient’s lives. We believe that the clinical adoption of innovative robotic solutions like Epione® will be a significant step toward allowing more patients to benefit from minimally invasive therapies in cancer treatment," said Bertin Nahum, President and Co-Founder of Quantum Surgical.

Epione® is a unique robotic-assisted technology designed to plan, target, deliver and confirm tumor ablation. Epione® enables clinicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which a needle is inserted through the skin to the tumor to destroy it.

“It is tremendous to see Epione® now available in the USA as I believe technology like this will have a meaningful impact in the Interventional Oncology space. Percutaneous tumor ablation is a proven therapy that is underutilized today, and Epione® will allow expansion of this minimally invasive treatment to more patients battling liver cancer,” said Nishita Kothary, Professor of Radiology at Stanford University Medical Center.

The FDA 510(k) clearance permits the commercial sale and the use of the Epione® interventional oncology robot in the United States to facilitate treatment of early-stage liver disease, a leading cause of cancer death. More than 3 million people are diagnosed with liver disease each year throughout the world. The company plans to extend indications for the Epione® platform to other organs and is developing artificial intelligence-based decision-support features.

“Epione® introduces an exciting new era by expanding technical ability and safety in the diagnosis and treatment of lesions anywhere in the liver,” added Prof. Steven Colquhoun, Liver Transplant Surgeon, who specializes in robotic surgery at Cedars-Sinai Medical Center.

This clearance is supported by clinical data from Prof. Thierry de Baere (Gustave Roussy Cancer Center, France) and Prof. Boris Guiu (Montpellier University Hospital, France), whose teams used the Epione® system to treat primary and secondary liver tumors.

Press releases

Gustave Roussy becomes the first center in the world to adopt Epione®, the medical robot designed to treat liver cancer

Montpellier, France, January 11, 2022 – The internationally renowned Gustave Roussy cancer center has become the first hospital globally to offer minimally invasive robotic procedures with the Epione® device, the medical robot developed by Quantum Surgical for liver cancer treatment.

This first contract between Quantum Surgical, an innovative company developing medical robots, and Gustave Roussy (Villejuif, France), Europe's leading cancer center, aims to enable more patients to benefit from Epione® for the minimally invasive treatment of abdominal tumors. This technique involves inserting a needle through the skin to destroy tumors.

Professor Thierry De Baere, head of the Therapeutic Imaging Department at Gustave Roussy, and his team will be the first in the world to use the Epione® robot in their routine clinical practice. Dr. De Baere is a world renowned expert in Interventional Oncology and he previously participated in the first clinical trial of Epione®, which successfully treated liver cancer robotically.

"Gustave Roussy is one of the world's leading cancer centers and we are proud to have them be Quantum Surgical's first customer of the Epione® robot. This installation will allow us to take a major step in cancer treatment by offering patients an innovative and minimally invasive treatment for liver tumors. Gustave Roussy is the ideal institution to partner with to showcase the potential of Epione® to help physicians perform safe and effective percutaneous tumor ablation in the abdomen and accelerate the clinical adoption of our medical robot," said Bertin Nahum, President and Co-Founder of Quantum Surgical.

"We look forward to evaluating new possibilities for minimally invasive treatment of small primary or secondary liver tumors for Gustave Roussy patients," said Professor Thierry De Baere, Head of the Therapeutic Imaging Department at Gustave Roussy and a member of Quantum Surgical's scientific advisory board.

Press releases

Quantum Surgical Secures 40 Million Euros to Support the Commercial Launch of Epione® Its unique Medical Robot

Montpellier, France, Oct 19th, 2021 - Quantum Surgical, an innovative medical robotic company, announced today that it has secured €40 million (US$48 million) of financing. Led by existing key investor Ally Bridge Group (“ABG”) with an investment of €20 million (US$24 million), this round also includes funding from the European Investment Bank, Bpifrance, and Caisse d'Epargne Languedoc Roussillon. This brings the total amount of funds completed by Quantum Surgical to €50 million since its inception.

Following CE mark approval announced in September, this funding will support company’s operations dedicated to the commercial launch of Epione®, a medical robot designed to assist physicians in performing safer and more efficient percutaneous tumor ablations in the abdomen. Epione® aims to allow more patients to benefit from minimally invasive liver cancer treatment, a technique consisting of inserting a needle percutaneously to burn a tumor.

"We are delighted to have closed this round of financing and honored by the strong, continued support of our key long-term investor Ally Bridge Group all the way since the days of our previous company Medtech SA just before its acquisition by Zimmer Biomet in 2016. These additional funds will support the company to accelerate the clinical adoption of Epione®, our medical robot for liver cancer treatment," said Bertin NAHUM, CEO, and co-founder of Quantum Surgical.

“As an early investor of Quantum Surgical, ABG is proud to continue to support the company’s impressive achievement throughout the Covid-19 pandemic, evidenced by its recent CE mark approval,” said Frank Yu, Founder, CEO and CIO at Ally Bridge Group. “We expect to see significant milestones to be achieved by Quantum in the near term that will allow Epione® to treat more liver cancer patients sooner and better than the current standard of care.”

“The EIB is pleased to contribute to the development of Quantum Surgical and its innovative technology to improve the treatment of liver cancer. Against the continued Covid-19 challenges, this €15 million funding, with the backing of the Pan European Guarantee Fund (EGF), demonstrates Europe's focus on supporting innovation and promising technologies in the field of healthcare, an area that is essential for people's well-being", said Ambroise Fayolle, vice-president of the European Investment Bank.

Press releases

Following CE Mark approval Quantum Surgical announces the commercial launch of Epione® its medical robot dedicated to liver cancer

Montpellier, France, September 7, 2021 - Quantum Surgical, an innovative medical robot-ics company, announces that it has recently obtained CE mark approval for Epione®, its robot designed for minimally invasive treatment of abdominal tumors. This authorization allows the commercial launch of Epione® on the European market.

Epione® is a robotic solution developed to help physicians perform safer and more effec-tive percutaneous ablations in the abdomen, a minimally invasive treatment in which a needle is inserted through the skin to the tumor to remove it. Epione® ensures reliability and accuracy, two key factors to improve current practice and reduce variability. Epione®, assists practitioners in managing patients, from preoperative planning to the end of the procedure.

The CE mark follows the successful treatment of 21 patients with the Epione® robot in a multi-center clinical study completed earlier this year.

"This is a major milestone for Quantum Surgical, as the CE mark approval is the starting point towards the commercialization of the robot. This clearance will allow many more patients to benefit from Epione® as there is a significant need for minimally invasive ther-apies in cancer treatment," declares Bertin NAHUM, CEO, and co-founder of Quantum Sur-gical.

Press releases

Professor Thierry De Baere to Join the Scientific Advisory Board of Quantum Surgical

Montpellier, France, May 17, 2021 - QuantumSurgical, an innovative medical robotic company, announced today the expansionof its Scientific Advisory Board (SAB) with the appointment of Pr. Thierry de Baere, Head of the Therapeutic Imaging Department atGustave Roussy, first cancer center in Europe.

The Quantum Surgical SAB is amulti-disciplinary board composed of international experts in the field ofimage-guided interventional oncology:

• Professor Steven D. Colquhoun (US), Liver transplant surgeon,specialized in robotic surgery at Cedars-Sinai Medical Center (Los Angeles, CA).

• Professor Thierry De Baere (FR), Head of theTherapeutic Imaging Department at Gustave Roussy Cancer Center (Villejuif).

• Professor Boris Guiu (FR), InterventionalRadiologist, Head of St Eloi Department of Diagnostic and InterventionalRadiology at Montpellier University Hospital (Montpellier).

• Professor Nishita Kothary (US), InterventionalRadiologist at Stanford University Medical Center (Stanford, CA).

• Professor David C. Madoff (US), InterventionalRadiologist at Yale New Haven Hospital (New Haven, CT).

Professor Luigi Solbiati (IT),InterventionalRadiologist, pioneer of percutaneous liver ablation techniques, Professor ofRadiology at Humanitas University (Rozzano - Milan), joins Professor GuyVallancien (FR), urology surgeon, and pioneer of laparoscopic and roboticsurgery, as honorary member of this Scientific Advisory Board.

Quantum Surgical is actively preparing to launch inEurope Epione®, a unique robotic platform designed to assist the physician inperforming safer and more efficient percutaneous thermal ablations in the liver(a minimally invasive treatment in which a needle is inserted through the skinto the malignancies to burn them).

We are honored anddelighted to expand our SAB with the appointment of Professor Thierry de Baere,who took part in our first clinical study in which 21 patients were successfullytreated in France,” declaresBertin Nahum, CEO, and co-founder of Quantum Surgical. “We will continue to benefitfrom precious advice provided by these internationally renowned physicians todevelop clinical adoption in the European and American markets.

Press releases

Quantum Surgical Completes First Clinical Study with Epione© Medical Robot

Montpellier, France, Tuesday February 16, 2021 - Quantum Surgical, an innovative surgical robotic company, announced today that it has successfully completed a first multicenter clinical study with its Epione® medical robot dedicated to minimally invasive liver cancer treatment.

The Epione® platform is designed to assist the physician in performing safer and more efficient percutaneous ablations in the liver (a minimally invasive treatment in which a needle is inserted through the skin to the lesion to burn it).

Professor Boris GUIU, Professor Thierry DE BAERE and their respective teams successfully treated 21 patients with the assistance of Epione® in this clinical trial carried out at Montpellier University Hospital (Montpellier, France) and at Gustave Roussy Cancer Center (Villejuif, France).

During these interventions, 24 liver tumors, whether they were primary (from the liver) or metastatic (from another organ) were successfully targeted and destroyed and furthermore the postoperative exams revealed no complications.

"The 21 patients treated were able to benefit from an innovative robotic guidance platform assisting in CT-guided percutaneous tumor destruction treatments. These patients were efficiently treated, pending definitive results which seem encouraging” explains Professor Boris GUIU, Interventional Radiologist, Head of the Department of Diagnostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital) and Professor Thierry DE BAERE, Head of the Therapeutic Imaging Department at Gustave Roussy.

"The completion of this first clinical trial is a key milestone to Epione’s® premarket approval” announces Bertin NAHUM, President and Founder of Quantum Surgical.

Press releases

First outpatient surgery with Epione®, Quantum Surgical's medical robot at Gustave Roussy Hospital

Montpellier, France, November 10, 2020 – On November 9, 2020 Professor Thierry de Baere and his team at Gustave Roussy Hospital (Therapeutic Imaging Department) successfully treated a patient with liver tumor on an outpatient basis using Quantum Surgical’s Epione® medical robot.

“Minimally invasive” interventions, which involves, among other factors, smaller incisions and adapted anesthesia methods compared to the so-called “conventional” procedures, reduces postoperative risks and patients, in turn, see a shorter recovery time. Outpatient surgery allows a person to return home on the same day that a surgical procedure is performed.

The development of outpatient interventions is a real step forward in terms of quality of care for patients. Unfortunately, this procedure is still not sufficiently developed in the World even though it could be convenient for many patients.

The Epione® platform aims to increase the number of patients who can benefit from percutaneous ablation of liver tumors (a minimally invasive treatment in which a needle is inserted through the skin to the lesion to burn it).

The first ambulatory patient treated with the assistance of Epione® is a key milestone for Quantum Surgical, as it illustrates the potential of its technology to contribute to value-based medicine through the development of outpatient care.

“It is always an immense pleasure and pride to work with a partner recognized as one of the best cancer hospitals in the world and to contribute with our technology to the development of outpatient care” explains Bertin Nahum, President, and co-founder of Quantum Surgical.

Press releases

Quantum Surgical receives a €200 000 “Pass Rebond” Grant from the Occitanie Region

Montpellier, France, Tuesday, September 22, 2020 – Quantum Surgical, an innovative company developing a robotic platform for the early treatment of liver cancer, announces that it has been awarded a €200,000 grant from the Occitanie Region.

This investment grant, awarded as part of the regional support plan for businesses known as the “Pass Rebond Occitanie,” is intended to support company development projects in anticipation of economic recovery following the Covid-19 health crisis.

The funding will enable the company to implement an Enterprise Resource Planning (ERP) system, which is essential for the upcoming market launch of its first product aimed at treating liver tumor lesions.

“We are extremely grateful for the support provided to businesses by the Occitanie Region, especially during this health crisis. This grant will allow us to continue developing our robotic platform, which is scheduled to be launched in 2021,” said Christophe Sibillin, Chief Financial Officer of Quantum Surgical.

Press releases

Historic intervention at Gustave Roussy Hospital: first liver metastases treated with Quantum Surgical's medical robot

Montpellier, France, July 9, 2020 - Professor Thierry de Baere and his team from the therapeutic imaging department of Gustave Roussy Hospital successfully treated, on July 7, 2020, a patient with liver metastases using Quantum Surgical's medical robot.

This successful intervention opens new perspectives for the treatment of patients with hepatic metastases (caused by cancers other than liver cancer) with the guidance of Quantum Surgical's medical robot.

Indeed, while liver cancer affects more than 800,000 new patients each year worldwide (1), liver metastases affect three times as many patients (2.4 million new patients each year worldwide (1)).

Quantum Surgical's device; a combination of powerful software and robotic platform, is designed to assist the physician in performing safer, more efficient and less invasive oncology treatments.

It is a "made in France" robotic platform, developed, designed and produced in Montpellier by Quantum Surgical, an innovative company co-founded and directed by Bertin Nahum, an experienced entrepreneur in medical robotics.

"Once its safety and performance on both primary liver tumors and liver metastases have been confirmed in the clinical trial, the device may prove to be a valuable aid in increasing the accuracy and widely disseminate less invasive percutaneous tumor destruction treatments for patients," explains Professor Thierry De Baere, Head of the therapeutic Imaging Department at Gustave Roussy Hospital.

"It is a pleasure and an honor to work with a French Top-Tier Hospital to expand our indications and allow more and more patients to benefit from robotic assistance for minimally invasive procedures," announces Bertin Nahum, President and Founder of Quantum Surgical.

(1) Globocan, 2018

Press releases

Quantum Surgical obtains Non-Dilutive Loan Facility of €4.8M

Montpellier, France, July 1, 2020 - Quantum Surgical, an innovative company developing a Surgical Robot for liver cancer treatment, announces today that the company has obtained a €4.8 million State Guaranteed Loan (PGE).

This loan, granted by Crédit Agricole, Dupuy de Parseval Bank, and the French Public Bank for Investment (BPI) as part of the measures to support the economy, will enable the company to pursue the development of its product which is expected to be commercialized in 2021 in Europe.

“Thanks to our partner banks and the BPI who quickly mobilized to grant us this loan, and thus confirm their confidence in our project, we will be able to continue our development activities aimed at obtaining Regulatory authorizations of our robotic platform needed before its commercialization” announces Christophe Sibillin, Chief Financial Officer at Quantum Surgical.

Webinar

Webinar on Robotics in Image Guided Ablation

Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.

Topics include:

  • Benefits and challenges of robotics during ablation procedures
  • Learning curves
  • How to approach administration about adopting robotics
  • Case presentations
  • And live Q&A
Join us for this virtual event with live Q&A.
Limited spots. 
REGISTER NOW!
Webinar

Webinar on Robotic- Assisted Ablation for Abdominal Tumors: Expert Perspectives and Case Reviews

Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.

The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.

Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.

Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.

The future of minimally invasive cancer treatment is today.